Also known as: MSN
Emerson Radio Corp. designs, sources, imports, markets, and sells houseware and consumer electronic products under the Emerson brand. The company also licenses its trademarks and sells through mass merchandisers and online marketplaces.
MSN Laboratories has received CDSCO approval for generic semaglutide, targeting a commercial launch by March 2026. The GLP-1 receptor agonist is used for type-2 diabetes management and will expand access to advanced metabolic therapies in India. The approval comes amid regulatory momentum and patent expirations driving generic entry into the market.
Natco Pharma has received approval from India's CDSCO to manufacture and market generic semaglutide injection, with a March 2026 launch planned. The approval comes amid patent litigation and intense competition in India's rapidly expanding diabetes and obesity drug market.
